ANASTROZOLE TEVA
|
|
Package:
TABLETS: 30.
Dosage:
Not recommended for children.
Adults including the elderly: One tablet 1 x daily. Renal impairment: No dose change is recommended in patients with mild or moderate impairment. Hepatic impairment: No dose change is recommended in patients with mild disease.
Prescribing Restrictions:
Indications:
Treatment of advanced breast cancer in postmenopausal women. Efficacy has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen.
Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer.
Adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
Contra-Indications:
Pre-menopausal women. Pregnancy, lactation. Severe renal impairment (creatinine clearance <20 ml/min). Moderate or severe hepatic disease. Known hypersensitivity to anastrozole or to any other ingredient of the preparation. Estrogen-containing therapies should not be co-administered as they would negate the pharmacological action. Concurrent tamoxifen therapy.
Special Precautions:
Pre-menopausal women. Pregnancy, lactation. Severe renal impairment (creatinine clearance <20 ml/min). Moderate or severe hepatic disease. Known hypersensitivity to anastrozole or to any other ingredient of the preparation. Estrogen-containing therapies should not be co-administered as they would negate the pharmacological action. Concurrent tamoxifen therapy.
Side Effects:
Pre-menopausal women. Pregnancy, lactation. Severe renal impairment (creatinine clearance <20 ml/min). Moderate or severe hepatic disease. Known hypersensitivity to anastrozole or to any other ingredient of the preparation. Estrogen-containing therapies should not be co-administered as they would negate the pharmacological action. Concurrent tamoxifen therapy.
Drug Interactions:
Estrogen-containing therapies, concurrent tamoxifen therapy. Please contact distributing company for full details.